financetom
Business
financetom
/
Business
/
Gautam Adani becomes Asia's second richest; Mukesh Ambani retains top slot
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Gautam Adani becomes Asia's second richest; Mukesh Ambani retains top slot
May 21, 2021 3:28 AM

Indian billionaires Mukesh Ambani and Gautam Adani are now the top two richest Asians, according to the recently released Bloomberg Billionaire Index. Mukesh Ambani, chairman of Reliance Industries Limited, has been holding the crown of Asia's richest man since February this year, and Adani has become the second richest in the continent leapfrogging China's billionaire Zhong Shanshan.

Share Market Live

NSE

The index reveals that Adani’s wealth more than doubled in the last few months to $66.5 billion following a sustained rise in the prices of listed Adani Group companies Adani Green, Adani Enterprises, Adani Gas, and Adani Transmission. Gautam Adani is now ahead of Chinese billionaire Zhong whose net worth is $63.6 billion.

According to the index, Adani’s wealth surge is the third-highest globally this year--LVMH head Bernard Arnault and Israeli-American physician Miriam Adelson saw an even bigger rise in their personal wealth.

Earlier this month, Adani Airports Holding said it had become the ‘largest Indian airport platform’ by catering to at least 10 percent of India’s air

Meanwhile, the net worth of Ambani stood at $76.5 billion, according to the index. This is despite a 'marginal' drop of $175.5 million in his wealth. Currently, Ambani is the 13th richest man in the world and Adani ranks 14th, according to the global billionaires' list of Bloomberg.

On the other hand, Zhong Shanshan, founder and chairman of Nongfu Spring beverage company and the majority owner of Beijing Wantai Biological Pharmacy Enterprise, witnessed a drop of $78 million in his income, according to the data shared by Bloomberg. He was once the sixth richest man in the world but his wealth has taken a hit in the past year.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sagimet Biosciences Q3 net loss narrows as costs drop
Sagimet Biosciences Q3 net loss narrows as costs drop
Nov 13, 2025
Overview * Sagimet reports Q3 net loss of $12.9 mln * R&D expenses for Q3 2025 decreased to $9.7 mln from $12.7 mln in Q3 2024 * Cash and equivalents stand at $125.5 mln as of September 30, 2025 Outlook * Sagimet anticipates Phase 1 trial data readout for denifanstat and resmetirom in 1H 2026 * Company plans Phase 2...
Arbutus Biopharma Q3 revenue and net loss miss analyst estimates
Arbutus Biopharma Q3 revenue and net loss miss analyst estimates
Nov 13, 2025
Overview * Arbutus Q3 revenue and net income missed analyst expectations * Company reports 46% of Phase 2a patients discontinued treatment in imdusiran trials * Arbutus continues litigation against Moderna and Pfizer/BioNTech over LNP technology Outlook * Favorable claim construction ruling in Pfizer-BioNTech litigation, Moderna trial set for March 2026 * 46% of Phase 2a patients discontinued treatment, showing potential...
Aldeyra Therapeutics Expands RASP Platform to Include Central Nervous System Diseases
Aldeyra Therapeutics Expands RASP Platform to Include Central Nervous System Diseases
Nov 13, 2025
07:41 AM EST, 11/13/2025 (MT Newswires) -- Aldeyra Therapeutics ( ALDX ) said Thursday it is expanding its RASP platform to include programs targeting central nervous system diseases associated with inflammation. The company said new preclinical results in models of Parkinson's disease and amyotrophic lateral sclerosis showed improved grip strength, balance, and biomarkers of central nervous system function. The results...
Top Premarket Gainers
Top Premarket Gainers
Nov 13, 2025
07:41 AM EST, 11/13/2025 (MT Newswires) -- Mersana Therapeutics ( MRSN ) stock was up more than three-fold pre-bell Thursday after the company agreed to be acquired by Day One Biopharmaceuticals (DAWN) in a deal worth $285 million. Sealed Air ( SEE ) shares were 21% higher after The Wall Street Journal reported late Wednesday that the company is in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved